Eagle Pharmaceuticals, inc. (EGRX)

[Bickema]

Ramblings on Why TEVA should acquire EGRX

Tariff has stated that earnings from BENDEKA are highly predictable for at least the next 3.5 years. So if we low ball that number at $30 million in revenue royalties from TEVA we get $420 million. So lets add in Eagles cash of roughly $127 million and we get $547 million

Also, over that time lets add $5 million a quarter in revenue from Ryanodex MH and the rest of Eagles's niche drugs, we get a total of $70 million

Over the next 3.5 years Eagle's cash and revenue value will equal roughly $617 million

So if we subtract that from Eagle's market cap of $1.1 billion we get an EV of $483 million for the rest of Eagle's pipeline which includes all sales from Bendeka and Ryanodex after 3.5 years. Pretty cheap if you ask me.

Thoughts or comments welcomed

P.S. go easy, I'm an amateur